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ABSTRACT :  
 
 
Background 
Accurate centre-level medication adherence measurement allows identification of highly performing 
CF centres, drives shared learning and informs quality improvement. Self-reported adherence is 
unreliable but data-logging nebulisers can capture objective data. However, adherence levels in 
current literature are limited by the use of agreed prescriptions and convenience sampling. In this 
single-centre retrospective study, we quantified the differences in centre-level adherence with 
different methods of calculating adherence (unadjusted vs normative adherence) and different data 
sampling frames (convenience sampling vs including difficult to obtain data). 
 
Methods 
Adherence data were objectively captured using I-neb® from 2013-2016 in Sheffield Adult CF Centre. 
Adults on non data-logging devices, on ivacaftor or with previous lung transplantation were excluded. 
Adherence was calculated based on agreed regimen (‘unadjusted adherence’) or minimum required 
regimen (‘normative adherence’). I-nebs® not brought to clinic were downloaded during home visits. 
Adults not on any inhaled therapy but with chronic Pseudomonas aeruginosa infection were included 
by counting their adherence as “0”. 
 
Results 
Of the 131 included adults, 126 provided I-neb® data. Calculating unadjusted adherence from I-
nebs® brought to clinics resulted in the highest centre-level adherence (median 41.8% in 2013). 
Median adherence reduced after sequentially accounting for minimum required regimen (40.0% in 
2013), I-nebs® not brought to clinics (32.9% in 2013) and adults not on any inhaled therapy (31.0% 
in 2013). 
 
Conclusions 
Different approaches of calculating adherence produced different adherence levels. Adherence 
levels based only on agreed regimen among adults who readily brought their nebulisers to clinics 
can over-estimate the effective adherence of CF centres. 
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Graphical abstract: Illustrating the sequential reduction in centre-level median adherence as various aspects of adherence data processing and 
analysis are being implemented to reflect treatment effectiveness using data from 2013 
 
 Sampling frame 1 
 
Only including adults who readily handed 
in their I-neb® 
Sampling frame 2 
 
Including all adults using I-neb® (i.e. also 
including I-neb® that were difficult to 
obtain) 
Sampling frame 3 
 
Including all adults using I-neb® and 
assigning the value of “0” for adults with 
chronic Pseudomonas aeruginosa infection 
but not using any CF inhaled therapies 
 
 
 
Unadjusted adherence 
 
Percentage of total nebulisers taken 
against the dose agreed between 
clinicians and adults with CF (i.e. the 
denominator is personalised rather than 
standardised)® 
 
 
 
   
 
 
 
Normative adherence 
 
Also calculated as a percentage, but 
standardised with denominator and 
numerator adjustments 
 
 
 
 
 
   
 
* The total number of eligible population in 2013 was 166 adults, as represented by the area of the shaded circle. 
  
† By only including adults who readily handed in their I-neb®, adherence would be calculated among 74 adults (the proportion of adults included are represented by 
the area of the white circle). The median unadjusted adherence was 41.8% and median normative adherence was 40.0%. 
 
‡ By including all adults using I-neb®, adherence would be calculated among 89 adults (the proportion of adults included are represented by the area of the white 
circle). The median unadjusted adherence was 36.9% and median normative adherence was 32.9%. 
 
Ω By including all adults using I-neb® and adults with chronic Pseudomonas aeruginosa infection not on any CF inhaled therapies, adherence would be calculated 
among 93 adults (the proportion of adults included are represented by the area of the white circle). The median unadjusted adherence was 35.1% and median 
normative adherence was 31.0%. 
* 
* 
* 
* 
* 
* 
41.8% †  36.9% ‡ 35.1% Ω 
40.0% †  32.9% ‡ 31.0% Ω 
1. INTRODUCTION 
 
Cystic fibrosis is a life-limiting genetic condition in which mortality is predominantly due to 
progressive lung damage driven by recurrent pulmonary exacerbations [1]. Inhaled therapies e.g. 
antibiotics and mucolytics are efficacious in preventing exacerbations and maintaining lung health 
[2]; but real-world median medication adherence of 35-50% among adults with CF is low [3, 4] 
especially in comparison to adherence of 80-100% in clinical trials [5]. The CF community is therefore 
unlikely to derive the optimal health benefits from inhaled therapies that were observed in clinical 
trials. Medication possession ratio of ~65% [6] in the presence of objectively measured adherence 
of ~35% [3] also highlights the possibility of significant waste. There are currently no effective 
adherence interventions for routine CF clinical use and the development of such interventions is a 
research priority [7].  
 
Various quality improvement (QI) initiatives have transformed the delivery of CF healthcare [8]. The 
expertise of CF community in QI can potentially be harnessed to support adherence by creating a 
learning health system [9] in which objectively measured adherence using data-logging nebulisers 
such as I-neb® and eTrack® informs benchmarking and shared learning [10]. Benchmarking allows 
centre comparisons to highlight variation in care and the identification of highly performing centres 
to learn from [11]. Though data-logging devices are more costly than standard nebulisers, a health 
economics evaluation suggest these devices will more than justify their costs if they are used 
effectively to provide feedback and improve adherence [12]. In the UK, NHS England specialised 
commissioning have agreed to fund objective adherence data capture across most adult English CF 
centres via the national Commissioning for Quality and Innovation (CQUIN) programme. A learning 
health system among these centres has been established (ISRCTN14464661) and is currently 
recruiting adults with CF in 19 out of the 28 UK centres. Therefore, understanding how to use 
objective adherence data as a quality indicator is an important and timely issue. 
 
Centre comparisons using adherence as a quality indicator rely on centres being confident that 
adherence measures are equally standardised, thus comparable between centres so that they 
accurately reflect the effective use of inhaled therapies within a centre. Though objective adherence 
data are accurate and reliable, robust comparison between centres also depends on how data are 
processed, analysed and reported. The ABC taxonomy for medication adherence recommends that 
adherence definitions should be clinically relevant and account for deviation that adversely influence 
the intended effects of medication regimen [13]. The Respiratory Effectiveness Group emphasises 
the importance of considering “successful medication adherence” holistically so that adherence 
levels reflect treatment effectiveness [14]. In general, inadequate prescription of efficacious 
treatment (“therapeutic inertia”) is the second biggest cause of ineffective treatment after low 
adherence [15]. Therapeutic inertia is pertinent in CF because “treatment burden” is widely perceived 
to be a major barrier to adherence [4]; with the result that treatment rationalisation or non-initiation 
of treatment can be one strategy that is adopted in the hope that a lowered treatment burden might 
promote greater engagement [16]. Another aspect of therapeutic inertia is appropriate inaction; such 
as treatment modifications due to medication intolerance, costs of medication, therapy being 
ineffective in the past and patient values/preference. Regardless of the reason(s) for excluding 
efficacious treatment(s) from an agreed prescription, there is the potential to reduce treatment 
effectiveness whilst inflating calculated adherence level unless there is standardisation against a 
normative adherence metric. For example, not initiating long-term inhaled antibiotics in a person with 
chronic Pseudomonas aeruginosa infection due to medication cost will result in a lowered 
denominator for calculating percent adherence and the resultant percent adherence is unlikely to 
reflect the effective utilisation of inhaled therapies (i.e. the denominator will be one daily dose instead 
of three daily doses assuming the person was already using dornase alfa and a twice daily inhaled 
antibiotic was not initiated). Adherence measures that incorporate treatment effectiveness are 
largely neglected in extant CF literature which tends to only report agreed adherence. Whilst agreed 
adherence is a valuable patient centred measure, its personalised nature undermines the 
standardisation required for centre comparison. 
 
Another limitation in extant literature is the use of convenience samples that ignores the group of 
people who are unwilling to share their data or who are not using any medication. People with the 
lowest adherence levels may be least willing to share their data [17]; hence centre comparisons 
would be confounded by inconsistent sampling frames and differential missing data unless the entire 
cohort is accounted for, such that the denominator used to calculate centre-level adherence is 
defined by all the appropriate patients making up the population of interest. In many studies, difficult-
to-reach patients would simply be missing and the missingness might well be unavoidably invisible 
for long-term conditions such as asthma. Yet CF is unique in that almost all people with CF in the 
UK are identified within the CF registry [18]. Registry data can identify the number of people who 
should actually feature as the centre denominator in centre-level adherence measurement and 
quantify the number of missing people in adherence levels calculated by each centre.  
 
Understanding the properties of different approaches to calculate centre-level adherence data is an 
important first step towards robust comparison using adherence as a quality indicator. We therefore 
set out to quantify the differences in centre-level adherence with different methods of calculating 
adherence and different data sampling frames. 
 
 
2. METHODS 
 
This single-centre retrospective analysis included all eligible adults with CF in Sheffield aged ≥16 
years diagnosed with the UK CF Trust criteria. Adults with lung transplantation or on ivacaftor were 
excluded because this dataset was originally compiled to evaluate the impact of adherence on health 
outcomes, and both treatments have transformative effects on lung health [19]. Adults using inhaled 
therapies via devices without data-logging capabilities were also excluded because only objective 
adherence levels were evaluated (the clinical characteristics of these adults were tabulated in 
Appendix A). However, adults with chronic Pseudomonas aeruginosa infection not on any CF inhaled 
therapies were included since they should have been on inhaled therapies. This study was approved 
by NHS Health Research Authority (IRAS number 210313). 
 
Inhaled therapy prescriptions and relevant demographic data (age, gender, genotype status [20], 
pancreatic status, CF related diabetes, Pseudomonas aeruginosa status as defined by the Leeds 
criteria [21], body mass index, %FEV1, intravenous antibiotics use) were extracted by two 
investigators independently reviewing paper notes and electronic records. Where extracted data 
differed, both investigators re-reviewed original data to arrive at a consensus. Nebuliser adherence 
data were downloaded from I-nebs®, which typically store 3,000-4,000 datapoints and provide date- 
and time-stamped data for every dose of nebulised medication [16].   
 
‘Unadjusted adherence’ was calculated as the percentage of total nebulisers taken against the dose 
agreed between clinicians and adults with CF (i.e. the denominator is personalised rather than 
standardised). ‘Normative adherence’ was also calculated as a percentage, but included 
denominator adjustment (standardised to define the minimum required treatment regimen) according 
to a person’s Pseudomonas aeruginosa status and numerator adjustments (capping daily maximum 
nebuliser use at 100%, accounting for doses taken after midnight and accounting for dose spacing 
for inhaled antibiotics) as previously described [22]. For example, those with chronic Pseudomonas 
aeruginosa infection should take at least a nebulised mucolytic and an antibiotic i.e. the 
denominator will be at least “3” (1x dornase alfa, 2x antibiotic). If that person only agreed to use 
dornase alfa once daily (i.e. 1 nebuliser/day), even if every dose was taken (giving 100% 
unadjusted adherence), the normative adherence would only be 33%. A detailed description for 
the calculation of normative adherence in a range of clinical scenarios is provided in Appendix B. 
 
For each adherence calculation method, centre-level adherence was determined as the median for 
all adults (i.e. adherence was calculated for every adult and the median for all adults was determined 
to avoid potential bias by differences in data duration between individuals). For each adherence 
calculation method, three sampling frames were applied to determine the centre-level adherence. 
First, adherence was calculated using only data from I-nebs® that were downloaded in each calendar 
year during clinical reviews, i.e. among adults who readily handed in their devices. Second, all 
available I-neb® data were used, i.e. including elusive I-nebs® that were “difficult to obtain” which had 
to be chased via repeated requests and home visits. This refers to I-nebs® that were not downloaded 
within the calendar year but data became retrospectively available when downloaded in subsequent 
year(s). These I-nebs® would have been a source of missing data without concerted efforts to retrieve 
them and would have remained missing in many settings. Therefore, the difficult to obtain I-nebs® 
were used to approximate the effect of ‘missing I-nebs® data’. Third, adherence levels also included 
adults with chronic Pseudomonas aeruginosa infection but not using any CF inhaled therapies 
throughout the calendar year by assigning their adherence as “0”.  
 
Analysis were performed using SPSS v25 (IBM Corp) and R v3.3.0 (www.r-project.org). Data for 
2013, 2014, 2015 and 2016 were analysed separately to determine the consistency of any 
observations. Appropriate descriptive statistics were generated. Where relevant, between-group 
comparisons were performed using non-parametric tests [23] (due to non-normal adherence data 
distribution and presence of outliers) whilst agreement between paired measurements were 
assessed with ‘difference vs average’ plots [24]. P-value <0.05 was considered statistically 
significant. The sample size was pragmatic, and all available data were included in this analysis.  
 
 
3. RESULTS 
 
This analysis included 131 adults, with 126 adults providing I-neb® data and five adults with chronic 
Pseudomonas aeruginosa infection but not on CF inhaled therapies. Year-by-year demographic data 
were stratified in Table 1 according to whether the adults used I-neb® or not. The number of adults 
with chronic Pseudomonas aeruginosa infection not on inhaled therapies was small. Around 1/3 of 
the adults in Sheffield used only non-data logging devices (31% in 2013, 28% in 2014, 30% in 2015 
and 37% in 2016) and were excluded from this analysis. Results in Appendix A suggest that these 
adults shared broadly similar clinical characteristics compared to adults included in this analysis. 
 
Although many of the unadjusted adherence values were similar to normative adherence, unadjusted 
values generally over-estimated adherence (see Figure 1 and Table 2). At a centre-level, the median 
paired differences were 2.6-5.1%. In those with low adherence (<5%), unadjusted and normative 
adherence differed little due to the floor effect of adherence (adherence level cannot be negative). 
However, in some adults with higher unadjusted adherence levels, the difference could be up to 40-
100% especially in those with nebuliser over-use (unadjusted adherence >100%) because daily 
adherence was capped at 100% for normative adherence. 
 
Despite the modest sample size, adherence levels for difficult to obtain I-nebs® (median normative 
adherence 8.4% in 2013, n=15; 9.8% in 2014, n=13; 6.1% in 2015, n=10; and 10.2% in 2016, n=8) 
were significantly lower than readily obtained I-nebs® (median normative adherence 40.0% in 2013, 
n=74; 45.2% in 2014, n=84; 49.6% in 2015, n=94; and 53.4% in 2016, n=94), Mann-Whitney p-value 
<0.001 for all four years. Thus measuring adherence using only readily obtained I-neb® over-
estimated centre-level adherence. Since difficult to obtain I-nebs® typically had such low adherence 
levels, adopting the convention of assigning their adherence levels as “0” would only result in very 
slight under-estimation of centre-level adherence (the resultant median normative adherence would 
be 30.6% in 2013, 41.0% in 2014, 44.6% in 2015 and 50.8% in 2016). Despite the small number of 
adults with chronic Pseudomonas aeruginosa infection who were not on any CF inhaled therapy, 
centre-level median adherence fell further if they were included in the overall estimate of adherence 
(see Table 2).  
4. DISCUSSION 
 
Once randomised controlled trials have demonstrated the efficacy of a treatment, it is reasonable to 
consider the proportion of eligible patients in a centre who are prescribed that treatment by clinicians 
and objectively captured adherence of patients to the prescription as an indicator of care quality. 
That is to say that once an RCT establishes a relationship between a process and an outcome, it is 
reasonable to use a process measure as an indicator of care quality. Our analysis empirically 
demonstrates that different approaches to processing and analysing objective data are likely to 
influence centre-level medication adherence. Medians are typically more robust to the impact of 
outliers [25], yet there was sequential reduction in centre-level median adherence as the analysis 
methodology moved from unadjusted adherence among readily obtained I-nebs® to normative 
adherence which included difficult to obtain I-nebs® and adults not on inhaled therapies when they 
should. Therefore, the considerations of both treatment appropriateness (normative adherence) and 
missing data (sampled via difficult-to-reach I-nebs®) are important in accurately understanding 
objective adherence as a centre-level quality indicator. 
 
In many long-term conditions, centre performance based on objective adherence and clinician 
prescribing patterns can be difficult to interpret, as the best centres might appear to have the worst 
adherence if therapeutic inertia is least prevalent and if they retain some engagement with difficult-
to-reach patients with the lowest medication adherence. An adolescent diabetic clinic where the most 
rebellious teenagers refuse to attend might have excellent glycosylated haemoglobin data; but that 
data is potentially misleading as an indicator of care quality without an understanding of the 
population that should have been reached. CF is unique in that the UK CF registry has data on 
almost all people with CF, thus the number of patients within a centre eligible for care (the centre 
denominator) is known, allowing CF to provide a unique setting for the study of intervention reach in 
long-term conditions.  
 
The high prevalence of missing data in studies investigating adherence has been reported previously 
[17]. Data are seldom missing at random and analyses in other long-term conditions also 
demonstrate the potential for missing data to introduce bias [26]. In our analysis, we have chosen to 
account for people not on any CF inhaled therapies by assigning “0” as their adherence level. This 
adjustment may be crude, but people not using any CF inhaled therapies when they should (since 
long-term inhaled antibiotics are recommended for chronic Pseudomonas aeruginosa infection) do 
have zero adherence. We also justify our approach by exploring the data of people on data-logging 
nebulisers who did not readily share their data. If a centre was not engaged in chasing down these 
data and simply omit difficult-to-reach I-nebs® from the centre denominator, an inappropriately high 
estimate of centre performance would be obtained. Assigning “transiently missing” adherence levels 
as “0” for the calculation of centre-level adherence in real time would only result in very slight under-
estimation since difficult-to-reach I-nebs® tended to have very low adherence levels.In addition to 
completely missing data, there is substantial variation in the prescription of inhaled therapies which 
is too large to be explained by just case-mix and chance. UK data showed an almost 3-fold difference 
(86.8% vs 30.2%) in the prescription of dornase alfa between the adult CF centres with highest and 
lowest use [18]. US data showed that only two-thirds of people with CF were prescribed the 
recommended inhaled therapies [27]. Since some of this variation reflects therapeutic inertia, it is 
important that treatment appropriateness is captured by standardisation according to patient 
characteristics via normative adherence. 
 
The extant CF literature tend to report unadjusted adherence levels from convenience samples 
without accounting for the appropriateness of treatment prescription or people with missing 
adherence data. This is likely to over-estimate centre-level adherence. In other words, although 
reported adherence levels among adults with CF in the literature are low at 35-50% [3, 4], the actual 
total cohort effective adherence levels are almost certainly even lower. This perspective is important 
in highlighting that the challenges of medication adherence may be even worse than published data 
suggest. With median centre-level objective adherence as low as 30%, centre comparisons and 
benchmarking within a learning health system that starts to drive improvement has the potential to 
make a major impact on the quality of care.  
 
Our findings have implications for benchmarking in justifying a standardised approach that allows 
objective adherence data to be used as a centre-level process measure suitable for quality 
measurement. The use of standardised process measure is important since using health outcomes 
as a quality measure for benchmarking in CF is particularly problematic because a relatively small 
UK CF population is spread across many centres. FEV1 is an important outcome measure in CF, but 
a recent sample size estimation suggests that 273 adults per centre are needed to detect a 5% FEV1 
difference at the 5% statistical significance level [28]. Yet only 6/28 (21.4%) of all UK adult CF centres 
have ≥273 adults [18]. CF QI initiatives focusing on process measures that allow rapid feedback to 
prompt improvement and subsequent reassessment have been reported,[8] but to date real time 
adherence data have not been exploited for this purpose. We hope that this study will lay the 
groundwork for such studies in the future. For any benchmarking exercises using adherence as a 
metric to be reliable, it is crucial to determine whether differences in the metric represents a genuine 
difference in effective adherence or whether it is merely an artefact of data issues (e.g. different 
prescribing practices between centres or differential missing data). The patient-centred unadjusted 
adherence measure based on personalised prescriptions reflecting individualised concordance is 
important when discussing adherence with individual patients but it is not a suitably standardised 
indicator for centre benchmarking. By using a standardised metric free from the vagaries of 
prescribing practices (normative adherence which is standardised in light of patients’ clinical 
characteristics) and missing data (standardised using registry data to define the centre denominator) 
to reflect treatment effectiveness, centres involved in the benchmarking exercise can be more 
confident that apples are being compared to apples.  
 
We acknowledge the uncertainty involved in deciding what inhaled therapies an adult with CF should 
be using based on their clinical characteristics. There are differing levels of evidence for inhaled 
therapies among people with differing lung disease severity and also for different treatment options. 
In our previous publication [22], we have taken the approach that perfect should not be the enemy 
of the good in attempting to specify an a priori method of processing adherence data which might be 
expected to ensure that a higher percentage adherence to the specified treatment regimen is 
associated with greater treatment effectiveness. The approach we have used will not capture all the 
subtleties involved in matching treatment regimens to complex patients; nevertheless the approach 
is pragmatic, can be applied in busy clinical setting, goes some way towards dealing with the issue 
of treatment effectiveness and goes much further in resolving issues around missing data. The 
Sheffield dataset was not large enough to definitively elucidate the relationship between health 
outcomes and different approaches of calculating adherence. Therefore, different adherence indices 
and methods of processing adherence data should be empirically tested in a suitably large dataset 
with objective adherence data and carefully measured key outcomes to determine the optimum 
method of calculating adherence levels. Nonetheless, different methods of adjusting for inadequate 
prescriptions would still find lower levels of adherence following the adjustments if efficacious 
treatments are under-prescribed. It is important to understand the direction of any bias. In this study, 
by only implementing denominator adjustments for adults with chronic Pseudomonas aeruginosa 
infection as defined by the Leeds criteria (which is known to lack sensitivity [29]), we are likely to 
under-adjust for required treatment prescription and hence our estimates of effective adherence is 
likely to be an over-estimation. Thus when adjustment lowers centre adherence, we can be confident 
that the revised figure is appropriately lowered and if anything, elimination of measurement bias (if 
technically possible) would merely lower it further. More thorough adjustments for other factors which 
influence treatment effectiveness would reveal even greater discrepancies between unadjusted and 
normative adherence. Another factor to consider in adjusting for treatment prescription is that not 
everyone would be able to tolerate inhaled therapies. It is uncertain whether the proportion of people 
with CF genuinely unable to tolerate any inhaled therapies will vary substantially from centre-to-
centre. Accounting for this group consistently across all centres should help to improve the reliability 
of centre-comparison with adherence as the metric for improvement.      
 
This study has other limitations. Objective adherence to dry powder inhalers (used by <10 adults 
each year in this single-centre cohort) and non-data logging nebulisers (e.g. eFlow®) could not be 
measured and were therefore excluded. However, the characteristics associated with adherence 
e.g. age and socioeconomic deprivation were broadly similar between the adults excluded because 
they were solely using devices without data-logging capabilities and adults using I-nebs®. Hence this 
exclusion may not necessarily bias the results and our analysis could still provide an insight into what 
data might be available if adherence were measured across the whole centre. Our sample size is 
pragmatic and single-centre studies may lack generalisability. Nonetheless, our dataset is currently 
the largest electronic data capture adherence dataset in CF with 18,303 weeks of adherence data 
from 126 adults. The consistency of our findings from 2013-2016 also provide some reassurance 
that the results are unlikely to occur just by chance. 
 
 
5. CONCLUSIONS 
 
We have demonstrated that objective adherence levels are influenced by the different approaches 
of sampling, processing and analysing adherence data. We have also proposed pragmatic methods 
to account for between-centre variation in treatment prescriptions and potential differential 
adherence data missingness, so that the resultant adherence metric better reflects the centre-level 
effectiveness of medication use. Standardising the approach of calculating adherence is an 
important first step towards robust centre-comparison to identify the relevant differences in structure 
and care processes that can stimulate improvement. After ensuring that adherence data between 
centres are comparable, understanding the case-mix factors which influence centre-level adherence 
is the next important step to make sense of the variation in adherence according to the ‘pyramid of 
investigation’ model [30]. Case-mix factors that influence adherence level will be the subject of our 
next paper. It has also not escaped our notice that the results in Table 2 suggest a consistent 
improvement in our centre’s adherence levels from 2013 to 2016, regardless of the metric used to 
report objective adherence. More detailed longitudinal analyses of our adherence data will be the 
subject of another paper. 
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Table 1: Clinical characteristics of study subjects 思 for 2013 to 2016 
 
 
 
 
 
Clinical 
characteristics 
 
2013 
 
2014 
 
2015 
 
2016 
 
Used  
I-neb® 
 
(n = 89) 
 
 
No  
nebuliser † 
 
(n = 4) 
 
Used  
I-neb® 
 
(n = 97) 
 
No  
nebuliser † 
 
(n = 3) 
 
Used  
I-neb® 
 
(n = 104) 
 
No  
nebuliser † 
 
 (n = 3) 
 
Used  
I-neb ® 
 
(n = 102) 
 
No  
nebuliser † 
 
(n = 0) 
 
Age in years, 
median (IQR) 
 
Female, n (%) 
 
Homozygous class 
I-III, ‡ n (%) 
 
Pancreatic 
insufficient, n (%) 
 
CF related 
diabetes, n (%) 
 
Chronic P. 
aeruginosa, ¶ n (%) 
 
 
BMI, median (IQR) 
 
 
Best %FEV1,§ 
median (IQR) 
 
IV antibiotic days,  
median (IQR) 
 
On inadequate 
prescription,Ω n (%) 
 
 
25 
(19 – 30) 
 
37 (41.6) 
 
80 (89.9) 
 
 
85 (95.5) 
 
 
23 (25.8) 
 
 
47 (52.8) 
 
21.5 
(19.7 – 24.3) 
 
75.9 
(52.9 – 90.0) 
 
14 (0 – 41) 
 
 
12 (13.5) 
 
28 
(26 – 31) 
 
2 (50.0) 
 
4 (100.0) 
 
 
4 (100.0) 
 
 
1 (25.0) 
 
 
4 (100.0) 
 
19.9 
(16.7 – 20.8) 
 
60.8 
(20.4 – 92.0) 
 
63 (21 – 95) 
 
 
4 (100.0) 
 
25 
(19 – 31) 
 
39 (40.2) 
 
88 (90.7) 
 
 
91 (93.8) 
 
 
25 (25.8) 
 
 
52 (53.6) 
 
22.2 
(20.1 – 24.3) 
 
74.0 
(55.0 – 87.5) 
 
14 (0 – 31) 
 
 
12 (12.4) 
 
29 
(29 – 31) 
 
2 (66.7) 
 
3 (100.0) 
 
 
3 (100.0) 
 
 
2 (66.7) 
 
 
3 (100.0) 
 
19.4 
(17.1 – 19.9) 
 
37.8 
(25.8 – 64.5) 
 
28 (21 – 56) 
 
 
3 (100.0) 
 
26 
(20 – 32) 
 
43 (41.3) 
 
91 (87.5) 
 
 
96 (92.3) 
 
 
25 (24.0) 
 
 
51 (49.0) 
 
23.0 
(20.7 – 24.9) 
 
76.0 
(58.5 – 87.6) 
 
20 (2 – 36) 
 
 
16 (15.4) 
 
43 
(39 – 46) 
 
2 (66.7) 
 
2 (66.7) 
 
 
2 (66.7) 
 
 
1 (33.3) 
 
 
3 (100.0) 
 
30.2 
(25.7 – 30.5) 
 
89.9 
(85.1 – 92.7) 
 
21 (11 – 46) 
 
 
3 (100.0) 
 
26 
(19 – 32) 
 
42 (41.2) 
 
91 (89.2) 
 
 
95 (93.1) 
 
 
32 (31.4) 
 
 
49 (48.0) 
 
23.2 
(20.6 – 25.4) 
 
76.4 
(62.1 – 87.0) 
 
18 (0 – 42) 
 
 
16 (15.7) 
 
N/A 
 
N/A 
 
N/A 
 
 
N/A 
 
 
N/A 
 
 
N/A 
 
 
N/A 
 
 
N/A 
 
 
N/A 
 
 
N/A 
 
思 Complete clinical characteristics data were available for all study subjects.   
 
† These are adults who should be on preventative inhaled therapies since they have chronic Pseudomonas aeruginosa 
infection but were not on any preventative inhaled therapies. 
 
‡ Genotype status was defined by international consensus [20]. Homozygous class I-III mutations indicate ‘severe 
genotype’. 
 
¶ The Leeds criteria were used to define Pseudomonas aeruginosa status [21]. 
 
§ This represents the highest %FEV1 reading (calculated with GLI equations) in the calendar year period.  
 
Ω A person with chronic Pseudomonas aeruginosa infection was deemed to be on inadequate prescription if he/she was 
not on at least once daily dose of mucolytic and at least twice daily doses of inhaled antibiotic (taking into account on/off 
long-term antibiotic regimens). In this group of people, denominator adjustment was required to calculate normative 
adherence. Everyone with chronic Pseudomonas aeruginosa infection not on any inhaled therapies was deemed to be on 
inadequate prescription.  
  
Table 2: The impact of different data analysis and processing methods on adherence levels for 2013 
to 2016 
 
 
Year 
 
2013 
 
 
2014 
 
 
2015 
 
 
2016 
 
 
Method 1:  
% unadjusted adherence , 
median (IQR) 
 
Sampling frame 1 †  
 
 
 
Sampling frame 2 ‡  
 
 
 
Sampling frame 3 Ω  
 
 
 
 
 
41.8 (25.8 – 70.0) 
n = 74 
 
36.9 (19.1 – 64.7) 
n = 89 
 
35.1 (16.9 – 64.3) 
n = 93 
 
 
 
 
52.6 (29.1 – 82.8) 
n = 84 
 
44.9 (19.3 – 77.1) 
n = 97 
 
44.7 (16.3 – 76.6) 
n = 100 
 
 
 
 
57.7 (28.4 – 85.5) 
n = 94 
 
51.4 (23.8 – 80.7) 
n = 104 
 
50.8 (22.0 – 80.2) 
n = 107 
 
 
 
 
59.1 (28.6 – 88.9) 
n = 94 
 
52.8 (24.3 – 88.0) 
n = 102 
 
52.8 (24.3 – 88.0) 
n = 102 
 
 
Method 2:  
% normative adherence , 
median (IQR) 
 
Sampling frame 1 †  
 
 
 
Sampling frame 2 ‡  
 
 
Sampling frame 3 Ω  
 
 
 
 
 
 
40.0 (20.4 – 67.2) 
n = 74 
 
32.9 (16.4 – 59.9) 
n = 89 
 
31.0 (15.1 – 58.1) 
n = 93 
 
 
 
 
45.2 (28.4 – 75.2) 
n = 84 
 
41.0 (17.2 – 65.4) 
n = 97 
 
39.7 (16.1 – 64.8) 
n = 100 
 
 
 
 
49.6 (23.1 – 80.1) 
n = 94 
 
45.4 (19.4 – 73.8) 
n = 104 
 
44.2 (18.8 – 69.6) 
n = 107 
 
 
 
 
53.4 (27.7 – 77.4) 
n = 94 
 
50.8 (23.8 – 71.6) 
n = 102 
 
50.8 (23.8 – 71.6) 
n = 102 
 
 
† Including adults who readily handed in their I-neb® 
 
‡ Including all adults using I-neb® (i.e. including I-neb® that were difficult to obtain) 
 
Ω Including all adults using I-neb® and assigning the value of “0” for adults with chronic Pseudomonas aeruginosa infection 
but not using any CF inhaled therapies 
 
 
 
 
 
  
Appendix A: Clinical characteristics of adults included in the analysis vs adults ex cluded due to the use of inhaled therapies via device s 
without data-logging capabilities 
 
In total, 84 adults were excluded from this analysis because they were only using CF inhaled therapies via devices without data-logging capabilities 
(e.g. eFlow® nebuliser or dry powder inhaler), i.e. their objective adherence were not measured. Their clinical characteristics were detailed in Table 1A. 
 
Table 1A: Clinical characteristics of adults included in the analysis vs adults using devices without data-logging capabilities for 2013 to 2016  
 
 
 
 
 
 
 
Clinical characteristics  
 
2013 
 
 
2014 
 
2015 
 
2016 
 
Adults included  
in the analysis 
 
(n = 93) 
 
Adults on non-
data logging 
devices   
 
(n = 42) 
 
 
Adults included  
in the analysis 
 
(n = 100) 
 
Adults on non-
data logging 
devices   
 
(n = 39) 
 
 
Adults included  
in the analysis 
 
(n = 107) 
 
Adults on non-
data logging 
devices   
 
(n = 46) 
 
 
Adults included  
in the analysis 
 
(n = 102) 
 
Adults on non-
data logging 
devices   
 
(n = 61) 
 
 
Age in years, median (IQR) 
 
Female, n (%) 
 
Homozygous class I-III, ‡ n (%) 
 
Pancreatic insufficient, n (%) 
 
CF related diabetes, n (%) 
 
Chronic P. aeruginosa, ¶ n (%) 
 
Deprivation quintile † 
      1 i.e. most affluent, n (%) 
      2, n (%) 
      3, n (%) 
      4, n (%) 
      5 i.e. most deprived, n (%) 
 
BMI, median (IQR) 
 
Best %FEV1, § median (IQR) 
 
IV antibiotic days, median (IQR) 
 
 
25 (19 – 30) 
 
39 (41.9) 
 
84 (90.3) 
 
89 (95.7) 
 
24 (25.8) 
 
51 (54.8) 
 
 
11 (11.8) 
8 (8.6) 
26 (28.0) 
21 (22.6) 
27 (29.0) 
 
21.3 (19.7 – 24.3) 
 
75.9 (52.7 – 90.0) 
 
14 (4 – 42) 
 
24 (20 – 30) 
 
19 (45.2) 
 
36 (85.7) 
 
37 (88.1) 
 
12 (28.6) 
 
18 (42.9) 
 
 
5 (11.9) 
4 (9.5) 
7 (16.7) 
12 (28.6) 
14 (33.3) 
 
21.5 (19.3 – 23.8) 
 
65.7 (46.8 – 92.3) 
 
14 (0 – 42) 
 
26 (19 – 31) 
 
41 (41.0) 
 
91 (91.0) 
 
94 (94.0) 
 
27 (27.0) 
 
55 (55.0) 
 
 
13 (13.0) 
10 (10.0) 
28 (28.0) 
25 (25.0) 
24 (24.0) 
 
22.1 (19.9 – 24.2) 
 
73.9 (54.2 – 87.5) 
 
14 (2 – 32) 
 
26 (21 – 33) 
 
21 (53.8) 
 
34 (87.2) 
 
34 (87.2) 
 
13 (33.3) 
 
22 (56.4) 
 
 
6 (15.4) 
3 (7.7) 
7 (17.9) 
8 (20.5) 
15 (38.5) 
 
22.1 (19.4 – 24.5) 
 
66.5 (34.9 – 89.8) 
 
14 (0 – 42) 
 
26 (20 – 32) 
 
45 (42.1) 
 
93 (86.9) 
 
98 (91.6) 
 
26 (24.3) 
 
54 (50.5) 
 
 
15 (14.0) 
10 (9.3) 
30 (28.0) 
26 (24.3) 
26 (24.3) 
 
23.0 (20.8 – 24.9) 
 
77.2 (59.1 – 87.7) 
 
21 (2 – 36) 
 
27 (23 – 34) 
 
27 (58.7) 
 
38 (82.6) 
 
38 (82.6) 
 
15 (32.6) 
 
26 (56.5) 
 
 
5 (10.9) 
5 (10.9) 
9 (19.6) 
12 (26.1) 
15 (32.6) 
 
21.5 (19.7 – 24.3) 
 
65.6 (41.9 – 86.1) 
 
17 (0 – 44) 
 
26 (20 – 32) 
 
42 (41.2) 
 
91 (89.2) 
 
95 (93.1) 
 
32 (31.4) 
 
49 (48.0) 
 
 
14 (13.7) 
11 (10.8) 
27 (26.5) 
24 (23.5) 
26 (25.5) 
 
23.2 (20.6 – 25.4) 
 
76.4 (62.1 – 87.0) 
 
18 (0 – 42) 
 
28 (23 – 35) 
 
37 (60.7) 
 
45 (73.8) 
 
45 (73.8) 
 
21 (34.4) 
 
30 (49.2) 
 
 
8 (13.1) 
9 (14.8) 
12 (19.7) 
16 (26.2) 
16 (26.2) 
 
22.0 (19.5 – 26.1) 
 
73.2 (47.0 – 87.5) 
 
14 (3 – 43) 
 
‡ Genotype status was defined by international consensus [1]. Homozygous class I-III mutations indicate ‘severe genotype’. 
 
¶ The Leeds criteria [2] were used to define Pseudomonas aeruginosa status. 
 
† These are Index of Multiple Deprivation (IMD) quintiles, which were derived from postcodes [3]. 
 
§ This represents the highest %FEV1 reading (calculated with GLI equations) in the calendar year period. One of the adults using non-data logging device did not provide any %FEV1 
readings from 2013 to 2016 due to the inability to perform spirometry. There is otherwise no missing data. 
  
For each year between 2013 and 2016, many more adults in Sheffield were using I-neb® compared 
to non-data logging devices because the Sheffield Adult CF Centre concentrated on finding ways to 
objectively quantify nebuliser use. There were no clear differences in terms of genotype, pancreatic 
status, CF related diabetes status and P. aeruginosa status between those on inhaled therapies via 
non-data logging devices and I-neb® users. However, %FEV1 was lower among non-data logging 
device users, in part because I-neb® (which is an adaptive aerosol device that only releases aerosol 
with an inhalation of sufficient quality [4]) can be a struggle to use among people with FEV1 <40%. 
 
For clinical characteristics that are associated with treatment adherence e.g. age [5] and 
socioeconomic status [6], there were broad similarities between non-data logging device users and 
I-neb® users. Majority of the adults in Sheffield were in the 19-25 years age range and <25% of the 
adults were in two most affluent socioeconomic quintiles. Though nebuliser adherence could not be 
objectively measured among non-data logging device users, it seems unlikely for them to have much 
higher adherence levels compared to I-neb® users since the clinical team in Sheffield paid the most 
attention to the adherence of adults with objective data.  
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Appendix B : A summary of the methods to calculate normative adherence 
 
The full details of the adjustments required to calculate normative adherence and the rationale for 
those adjustments are outlined in our previous paper [1]. To calculate normative adherence, the 
numerator was initially adjusted for the following: 
1. accounting for incomplete doses – a “full” dose was counted as “1 dose”, “12.5%–100%” was 
counted as “½ dose” while “<12.5%” and “none” doses were counted as 0 
2. capping maximum daily dose at 100% according to prescribed doses –  nebuliser use in excess 
of the agreed dose was not counted 
3. accounting for doses taken after midnight – counting a day as starting at 5am and ending at 
4.59am 
4. accounting for device dose delivery characteristics – each complete nebulisation of tobramycin 
solution via the I-neb® was counted as “½ dose”, so that the complete dose (two complete 
nebulisations) would count as “1 dose” 
5. minimum dose spacing for inhaled antibiotics – inhaled antibiotic doses that were used <6 hours 
after an initial dose were not counted 
 
The denominator was then adjusted according to the following rules: 
1. For every study subject, their Pseudomonas aeruginosa status was determined using the Leeds 
criteria [2]. 
2. For every study subject identified as not having chronic P. aeruginosa infection, no denominator 
adjustment was carried out.  
3. For every study subject identified as having chronic P. aeruginosa infection, the minimum 
denominator was set at once daily mucolytic and twice daily antibiotics (taking into account on/off 
long-term antibiotic regimens). For example, in a study subject with chronic P. aeruginosa 
infection but only prescribed mucolytic, two extra nebuliser doses per day will be added to the 
denominator. For someone with chronic P. aeruginosa infection but only prescribed twice daily 
antibiotic without any mucolytic, one extra nebuliser dose per day will be added to the 
denominator.  
 
Of note, denominator adjustments were only carried out among adults with chronic P. aeruginosa 
infection if they were not already on at least one daily dose of mucolytic and at least two daily doses 
of antibiotics (taking in account on/off long-term antibiotic regimens). There would be no denominator 
adjustment if the minimum required doses were already fulfilled, for example in someone who was 
already on twice daily hypertonic saline and thrice daily Aztreonam. As such, whilst there may be 
some variation in the calculated normative adherence according to differences in prescribing 
practices, this variation is unlikely to be significant. For example, someone with chronic P. 
aeruginosa infection but using their prescribed once daily dornase alfa with 100% unadjusted 
adherence would have normative adherence of 33%, whereas someone with chronic P. aeruginosa 
infection only on hypertonic saline twice daily with 100% unadjusted adherence would have 
normative adherence of 50%. The median unadjusted adherence of only ~50% among the study 
subjects would reduce the absolute difference in normative adherence. The two people in the 
example above would have normative adherence of 17% and 25% respectively if their unadjusted 
adherence was 50%, or normative adherence of 8% and 13% respectively if their unadjusted 
adherence was 25%. The full details for the denominator adjustments of the cohort are detailed in 
Table 1B.  
 
Table 1B: Full details of the denominator adjustments from 2013 to 2016 
 
 
 
 
The actual prescription  † 
 
 
The denominator 
adjustment that was 
carried out 
 
Number of adults using I-neb ® with this  
denominator adjustment for each year, n  (%) 
 
2013  
(n = 89) 
 
2014 
(n = 97) 
2015 
(n = 104) 
2016 
(n = 102) 
 
(Not chronic Pseudomonas 
aeruginosa infection) 
 
 
No denominator 
adjustment 
 
 
42 (47.2) 
 
 
45 (46.4) 
 
 
53 (51.0) 
 
 
53 (52.0) 
 
(Chronic Pseudomonas 
aeruginosa infection, 
already on at least once 
daily dose of mucolytic and 
twice daily doses of 
inhaled antibiotic, taking 
into account on/off long-
term antibiotic regimens) 
 
 
 
 
 
No denominator 
adjustment 
 
 
 
 
 
35 (39.3) 
 
 
 
 
 
40 (41.2) 
 
 
 
 
 
35 (33.7) 
 
 
 
 
 
33 (32.4) 
 
Chronic Pseudomonas 
aeruginosa infection, on 
inadequate prescription 
 
 
Once daily dornase alfa  
 
 
 
 
Once daily dornase alfa 
(was on month-on / month-
off tobramycin which was 
stopped between May and 
July 2013) 
 
 
 
Once daily colistin 
(Promixin®) 
 
 
 
Twice daily colistin 
(Promixin®) 
 
 
 
 
Daily normative 
denominator of “3” (instead 
of “1”) 
 
Daily normative 
denominator of “3” ‡ 
(instead of “1”) for the 
month of June 2013, 
otherwise no denominator 
adjustment 
 
Daily normative 
denominator of “3” (instead 
of “1”) 
 
Daily normative 
denominator of “3” (instead 
of “2”) 
   
 
 
 
 
 
 
4 (4.5) 
 
 
 
 
 
1 (1.1) 
 
 
 
 
 
0 
 
 
 
7 (7.9)  
 
 
 
 
 
 
3 (3.1) 
 
 
 
 
 
0 
 
 
 
 
 
0 
 
 
 
9 (9.3)  
 
 
 
 
 
 
3 (2.9) 
 
 
 
 
 
0 
 
 
 
 
 
1 (1.0) 
 
 
 
12 (11.5)  
 
 
 
 
 
 
7 (6.9) 
 
 
 
 
 
0 
 
 
 
 
 
0 
 
 
 
9 (8.8)  
 
† Aztreonam was not nebulised through an I-neb®, hence no adjustments for people on Aztreonam was required. However, 
the same principle applies for calculating normative adherence with other devices (e.g. an eTrack®). For example, if 
someone with chronic Pseudomonas aeruginosa infection was only on thrice daily Aztreonam nebuliser, then the normative 
adherence convention would be to add an extra dose to the normative denominator to account for the missing mucolytic 
(i.e. daily normative denominator of “4” instead of “3”). In addition, very few of the cohort were on on-off inhaled antibiotics 
regimen since it is not the centre practise to recommend this and few of the cohort were on nebulised hypertonic saline 
since dornase alfa is the first choice mucolytic for the centre. Of note, there was no much denominator adjustments in our 
centre because we have an agreed strategy of using normative regimens universally where possible. In centres where 
therapeutic inertia is more common, there would be a larger proportion of people with CF requiring denominator 
adjustments.  
 
‡ Tobramycin requires double-loading via an I-neb® for adequate dosing but numerator adjustment accounting for device 
dose delivery characteristics converts a complete Tobramycin dose (i.e. two complete nebulisations) into “1 dose”, hence 
the normative denominator stays at “3” instead of “5” for someone using twice daily tobramycin and once daily dornase 
alfa via an I-neb®.  
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